JP2016509029A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509029A5
JP2016509029A5 JP2015558205A JP2015558205A JP2016509029A5 JP 2016509029 A5 JP2016509029 A5 JP 2016509029A5 JP 2015558205 A JP2015558205 A JP 2015558205A JP 2015558205 A JP2015558205 A JP 2015558205A JP 2016509029 A5 JP2016509029 A5 JP 2016509029A5
Authority
JP
Japan
Prior art keywords
chlorophenyl
morpholinyl
oxo
bis
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509029A (ja
JP6417338B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016971 external-priority patent/WO2014130470A1/en
Publication of JP2016509029A publication Critical patent/JP2016509029A/ja
Publication of JP2016509029A5 publication Critical patent/JP2016509029A5/ja
Application granted granted Critical
Publication of JP6417338B2 publication Critical patent/JP6417338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558205A 2013-02-19 2014-02-18 癌の治療のためのmdm2阻害剤としてのシス−モルホリノン及び他の化合物 Active JP6417338B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766625P 2013-02-19 2013-02-19
US61/766,625 2013-02-19
PCT/US2014/016971 WO2014130470A1 (en) 2013-02-19 2014-02-18 Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016509029A JP2016509029A (ja) 2016-03-24
JP2016509029A5 true JP2016509029A5 (enExample) 2017-03-02
JP6417338B2 JP6417338B2 (ja) 2018-11-07

Family

ID=50236309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558205A Active JP6417338B2 (ja) 2013-02-19 2014-02-18 癌の治療のためのmdm2阻害剤としてのシス−モルホリノン及び他の化合物

Country Status (7)

Country Link
US (1) US20160002185A1 (enExample)
EP (1) EP2958902B1 (enExample)
JP (1) JP6417338B2 (enExample)
AU (1) AU2014219075C1 (enExample)
CA (1) CA2901696C (enExample)
MX (1) MX362896B (enExample)
WO (1) WO2014130470A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としての複素環化合物
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX378969B (es) 2013-11-11 2025-03-11 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3246148A1 (de) * 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2005295441B2 (en) 2004-10-18 2009-04-23 Amgen, Inc. Thiadiazole compounds and methods of use
WO2007084391A2 (en) 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
US7919498B2 (en) 2007-03-23 2011-04-05 Amgen Inc. Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
CA2692720A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP5530422B2 (ja) 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド 細胞周期阻害薬としてのgem−二置換およびスピロ環式アミノピリジン/ピリミジン
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
WO2010096314A1 (en) 2009-02-18 2010-08-26 Amgen Inc. INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
MX2011013667A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
WO2010151791A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
JP6093770B2 (ja) * 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としての複素環化合物

Similar Documents

Publication Publication Date Title
JP2016509029A5 (enExample)
JP2009519340A5 (enExample)
NZ724602A (en) Ror-gamma modulators and uses thereof
CN102933564B (zh) 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物
JP2016503786A5 (enExample)
JP2005536475A5 (enExample)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
US20240132487A1 (en) Substituted azacyles as trmp8 modulators
RU2008141510A (ru) Новые соединения
JP2013532713A5 (enExample)
JP2017515844A5 (enExample)
WO2012048181A4 (en) Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
CA2665476A1 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
CA2785341A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
JP2014532640A5 (enExample)
HRP20150082T1 (hr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
JP2008504266A5 (enExample)
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2017512794A5 (enExample)
SI2970155T1 (en) INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO)
RU2728823C1 (ru) Фенильные производные в качестве агонистов каннабиноидного рецептора 2
JP2011529037A5 (enExample)
IL278642B2 (en) Furin inhibitors
JP2013530957A5 (enExample)
JP2016518344A5 (enExample)